Coeliac Disease Trial, Recruiting NCT03024775 Sponsor: University of Palermo Condition: Coeliac Disease
Back to Coeliac Disease

Coeliac Disease Trial, Recruiting

NCT03024775
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your blood tests for certain antibodies related to celiac disease (anti-tissue transglutaminase and antiendomysium antibodies) have come back negative
  • A gut examination has shown that the lining of your small intestine is normal, with no damage to the tiny finger-like structures (villi) that help absorb nutrients
  • Allergy tests for wheat (such as a skin prick test or blood test) have come back negative, ruling out a traditional wheat allergy
  • You have been monitored for more than 12 months since first being diagnosed with your condition
  • You have had at least two check-up appointments during that monitoring period
  • Your digestive symptoms improved when you stopped eating certain foods, including wheat, cow's milk, eggs, tomatoes, chocolate, or other foods that seemed to cause problems
  • Your symptoms came back during a controlled, blinded food challenge test where you were given wheat without knowing it (confirm with trial site)

Who may not be able to join:

  • You are under 18 years of age
  • A special laboratory test on a sample taken from your small intestine showed a positive result for a certain antibody (EmA), even if the gut lining otherwise looked normal (confirm with trial site)
  • You have already removed wheat from your diet on your own and are not willing to reintroduce it before the study begins
  • You have another known digestive condition, such as Crohn's disease
  • You are currently taking steroid medications or antihistamines

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Antonio Carroccio, PhD, University of Palermo

Phone: +390916552884

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Palermo
Registry
ClinicalTrials.gov
Start date
1 January 2017
Est. completion
1 June 2024

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Inflammatory response to wheat genotypes by PBMC of NCWS patients and healthy control subjects.; Inflammatory response to wheat genotypes by rectal immunocytes of NCWS patients and healthy control subjects.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov